术前β受体阻滞剂与严重肢体缺血患者下肢血运重建后30天主要不良心脏事件增加相关
基于2011至2014年NSQIP血管靶向文件,分析11785例因严重肢体缺血(CLI)行下肢血运重建的患者,比较术前使用与未使用β受体阻滞剂者的30天主要不良心脏事件(MACE)和主要不良肢体事件(MALE)。结果显示术前β受体阻滞剂与MACE和心肌梗死(MI)显著增加独立相关,但不影响MALE。
要点
- 术前β受体阻滞剂独立预测30天MACE(OR 1.27)和MI(OR 1.36)。
- β受体阻滞剂与30天MALE无显著关联(OR 0.99)。
- β受体阻滞剂未显著影响卒中或30天死亡率。
核心结论
- 在CLI患者中,控制其他心血管危险因素后,术前β受体阻滞剂是30天MI和MACE的独立预测因素。
- β受体阻滞剂对短期肢体相关结局无影响。
研究设计与样本
- 回顾性队列研究,使用2011至2014年NSQIP血管靶向文件。
- 共纳入11785例因CLI行下肢血运重建的患者(7408例旁路手术 vs 4377例腔内介入)。
- 比较术前使用与未使用β受体阻滞剂患者的30天MACE和MALE,并用多因素logistic回归识别独立预测因素。
主要发现
- 术前β受体阻滞剂使用率为7365例,其中开放旁路组4541例(61.7%),腔内组2824例(64.5%)(P < .01)。
- 术前β受体阻滞剂组MACE发生率5.8% vs 3.4%(P < .0001),MI发生率3.1% vs 1.8%(P < .0001)。
- 多因素分析:β受体阻滞剂独立预测MACE(OR 1.27;P = .03)和MI(OR 1.36;P = .03),但不预测卒中(OR 1.17;P = .58)或30天死亡(OR 1.22;P = .19)。
- β受体阻滞剂对MALE无影响(OR 0.99;P = .88)。
临床怎么用
- 对于因CLI行下肢血运重建的患者,术前使用β受体阻滞剂需权衡心脏获益与围手术期MACE风险。
- 不应期望β受体阻滞剂改善短期肢体相关结局。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The association between beta blockers and cardiovascular or limb-related outcomes after revascularization for critical limb ischemia (CLI) remains unclear. The objective of this study was to assess the impact of preoperative beta blockade on 30-day major adverse cardiac events (MACEs) and major adverse limb events (MALEs) in patients undergoing infrainguinal revascularization for CLI. We hypothesized that rates of MALEs and MACEs will be higher in patients not receiving preoperative beta blockade. METHODS: The National Surgical Quality Improvement Program vascular targeted file for 2011 to 2014 identified patients receiving beta blockade and undergoing infrainguinal endovascular intervention and open bypass for CLI. Primary outcomes including 30-day MACE (stroke, myocardial infarction [MI], or death) and MALE (untreated loss of patency, reintervention, or amputation) were compared between patients taking and not taking preoperative beta blockers. Multivariate logistic regression identified independent predictors of MACEs and MALEs. RESULTS: A total of 11,785 revascularizations were performed for CLI during the study period (7408 bypasses vs 4377 endovascular interventions). Preoperative beta blockers were used by 7365 patients, including 4541 (61.7%) in the open bypass cohort and 2824 (64.5%) in the endovascular group (P < .01). MACEs and MI were significantly higher in patients with preoperative beta blockers (MACEs, 5.8% vs 3.4% [P < .0001]; MI, 3.1% vs 1.8% [P < .0001]). After controlling for cardiac risk factors, beta blockers independently predicted MACEs (odds ratio [OR], 1.27; P = .03) and MI (OR, 1.36; P = .03) but not stroke (OR, 1.17; P = .58) or 30-day mortality (OR, 1.22; P = .19). Beta-blocker use did not have an effect on MALEs (OR, 0.99; P = .88). CONCLUSIONS: In patients with CLI, preoperative beta blockade was an independent predictor of 30-day MI and MACEs after controlling for other cardiovascular risk factors. Beta blockers did not have an impact on short-term limb-related outcomes. The association between beta blockade and revascularization for CLI deserves further investigation.
引用
- Shannon AH, Mehaffey JH, Cullen JM, et al. Preoperative beta blockade is associated with increased rates of 30-day major adverse cardiac events in critical limb ischemia patients undergoing infrainguinal revascularization. J Vasc Surg. 2018. PMID: 30598355. doi:10.1016/j.jvs.2018.07.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。